Invert Graphite Limited has released a press release.
Management Change
Filed with ASX ·
6ix hasn’t read this filing yet.
Invert Graphite Limited on 6ix
Earlier from Invert Graphite
- Results of Phase 2 Clinical Trial
- Appendix 4C - September 2018 Quarter
- Factor Therapeutics Appoints Transaction Advisor
- Last patient completes treatment in VLU Ph 2 Clinical Trial
- Half Yearly Report and Accounts
Later from Invert Graphite
- Appendix 4C - December quarter
- Update regarding anticipated R&D tax incentive rebate
- Placement completed to support future direction of Factor
- Annual Report for Financial Year to 31 Dec 2018
- Response to ASX Query
Follow Invert Graphite into a list and get an email when it puts out news.
Follow Invert Graphite